OtherClinical Investigations (Human)
PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617
Clemens Kratochwil, Frederik L. Giesel, Melsa Stefanova, Martina Benešová, Marcus Bronzel, Ali Afshar-Oromieh, Walter Mier, Matthias Eder, Klaus Kopka and Uwe Haberkorn
Journal of Nuclear Medicine March 2016, jnumed.115.171397; DOI: https://doi.org/10.2967/jnumed.115.171397
Clemens Kratochwil
1 University Hospital Heidelberg, Germany;
Frederik L. Giesel
1 University Hospital Heidelberg, Germany;
Melsa Stefanova
1 University Hospital Heidelberg, Germany;
Martina Benešová
2 German Cancer Research Center (dkfz);
Marcus Bronzel
3 ABX-CRO
Ali Afshar-Oromieh
1 University Hospital Heidelberg, Germany;
Walter Mier
1 University Hospital Heidelberg, Germany;
Matthias Eder
2 German Cancer Research Center (dkfz);
Klaus Kopka
2 German Cancer Research Center (dkfz);
Uwe Haberkorn
1 University Hospital Heidelberg, Germany;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617
Clemens Kratochwil, Frederik L. Giesel, Melsa Stefanova, Martina Benešová, Marcus Bronzel, Ali Afshar-Oromieh, Walter Mier, Matthias Eder, Klaus Kopka, Uwe Haberkorn
Journal of Nuclear Medicine Mar 2016, jnumed.115.171397; DOI: 10.2967/jnumed.115.171397
PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617
Clemens Kratochwil, Frederik L. Giesel, Melsa Stefanova, Martina Benešová, Marcus Bronzel, Ali Afshar-Oromieh, Walter Mier, Matthias Eder, Klaus Kopka, Uwe Haberkorn
Journal of Nuclear Medicine Mar 2016, jnumed.115.171397; DOI: 10.2967/jnumed.115.171397
Jump to section
Related Articles
Cited By...
- Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
- Optimized Methods for the Production of High-Purity 203Pb Using Electroplated Thallium Targets
- Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer
- Evolution of Models of Prostate Cancer: Their Contribution to Current Therapies
- Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
- Effects of 225Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis
- Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
- The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
- An Improved 211At-Labeled Agent for PSMA-Targeted {alpha}-Therapy
- Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
- Radionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics
- To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy
- Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
- TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid Tumors
- 177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer
- Digital Solid-State SPECT/CT Quantitation of Absolute 177Lu Radiotracer Concentration: In Vivo and In Vitro Validation
- 177Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer
- Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors
- JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy
- Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
- Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
- Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction
- Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes
- Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics
- 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
- Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody
- Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands
- First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands
- Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy
- Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617
- Modeling and Predicting Tumor Response in Radioligand Therapy
- The Relevance of Dosimetry in Precision Medicine
- Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer
- Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing 177Lu-PSMA Therapy
- The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?
- Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging
- Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq
- Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
- Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
- Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
- 177Lu-PSMA Radioligand Therapy for Prostate Cancer
- Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?
- Why Targeting of PSMA Is a Valuable Addition to the Management of Castration-Resistant Prostate Cancer: The Urologists Point of View
- Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18F-DCFPyL: Variability in Normal-Organ Uptake
- Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging
- Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
- 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept
- Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
- 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience
- German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
- PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
- Imaging approaches to optimize molecular therapies